Chinese Medicine Treat for Hypertensive Renal Injury
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 520 participants.
Also called NCT04078711
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 520 participants
- Sponsor
- Registry
-
NCT04078711
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT04078711. Randomized; double masking; primary purpose treatment. Start 2019-09-10 (anticipated); primary completion 2021-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Chinese Medicine Treat for Hypertensive Renal Injury
- Acronym
- CHAIR
- Condition
- Hypertension
- Condition
- Renal Injury
- Intervention (Drug)
- Losartan 100Mg Tab
- Intervention (Drug)
- Qianyangyuyin 20g Granule
- Intervention (Drug)
- placebo
- Lead sponsor
- Jiangsu Province Hospital of Traditional Chinese Medicine
- Collaborator
- Ministry of Science and Technology of the People´s Republic of China
- Collaborator
- Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
- Collaborator
- The First Affiliated Hospital of Henan University of Traditional Chinese Medicine
Record details
- Record id
cardio:ct-nct04078711- Content hash
52b39f472c9f098d7b0e3e9132c41b4012c2d0b1c3173cec3a0732f8c09a0a31